SG11202112537YA - A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator - Google Patents
A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulatorInfo
- Publication number
- SG11202112537YA SG11202112537YA SG11202112537YA SG11202112537YA SG11202112537YA SG 11202112537Y A SG11202112537Y A SG 11202112537YA SG 11202112537Y A SG11202112537Y A SG 11202112537YA SG 11202112537Y A SG11202112537Y A SG 11202112537YA SG 11202112537Y A SG11202112537Y A SG 11202112537YA
- Authority
- SG
- Singapore
- Prior art keywords
- positive allosteric
- allosteric modulator
- tetrahydroisoquinoline derivative
- substituted tetrahydroisoquinoline
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19183643 | 2019-07-01 | ||
| PCT/EP2020/068183 WO2021001288A1 (en) | 2019-07-01 | 2020-06-29 | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112537YA true SG11202112537YA (en) | 2021-12-30 |
Family
ID=67137843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112537YA SG11202112537YA (en) | 2019-07-01 | 2020-06-29 | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220259179A1 (en) |
| EP (1) | EP3993794A1 (en) |
| JP (1) | JP2022539152A (en) |
| KR (1) | KR20220029686A (en) |
| CN (2) | CN113993857B (en) |
| AR (1) | AR119318A1 (en) |
| AU (1) | AU2020299953A1 (en) |
| BR (1) | BR112021022378A2 (en) |
| CA (1) | CA3139571A1 (en) |
| CL (1) | CL2021002946A1 (en) |
| CO (1) | CO2021018155A2 (en) |
| EC (1) | ECSP21093559A (en) |
| IL (1) | IL289314A (en) |
| MA (1) | MA56440A (en) |
| MX (1) | MX2021015873A (en) |
| PE (1) | PE20221020A1 (en) |
| SG (1) | SG11202112537YA (en) |
| TW (1) | TW202115010A (en) |
| WO (1) | WO2021001288A1 (en) |
| ZA (1) | ZA202109193B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021401128A1 (en) | 2020-12-18 | 2023-07-13 | UCB Biopharma SRL | Amorphous solid dispersions |
| WO2022129356A1 (en) | 2020-12-18 | 2022-06-23 | UCB Biopharma SRL | Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone |
| MX2023007155A (en) | 2020-12-18 | 2023-06-28 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator. |
| KR20230154968A (en) * | 2021-03-09 | 2023-11-09 | 일라이 릴리 앤드 캄파니 | Use of mevidalen and other D1 positive allosteric modulators to slow the progression of Parkinson's disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101668746A (en) | 2007-03-01 | 2010-03-10 | 詹森药业有限公司 | As histamine H 3The tetrahydro isoquinoline compound of receptor modulators |
| KR101284796B1 (en) | 2011-10-05 | 2013-07-10 | (주)포인트엔지니어링 | method for light emitting device with can package and the light emitting device |
| JO3316B1 (en) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | 3,4-dihydroisoquinolin-2(1h)-yl compounds |
| CN107001278B (en) | 2014-10-08 | 2020-11-24 | Ucb生物制药私人有限公司 | Tetrahydroisoquinoline derivatives |
| JP6908623B2 (en) * | 2016-04-13 | 2021-07-28 | ユーシービー バイオファルマ エスアールエル | Tetrahydroisoquinoline derivative |
| TWI725408B (en) | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | Dopamine d1 receptor positive allosteric modulators |
-
2020
- 2020-06-29 CA CA3139571A patent/CA3139571A1/en active Pending
- 2020-06-29 BR BR112021022378A patent/BR112021022378A2/en unknown
- 2020-06-29 CN CN202080043657.XA patent/CN113993857B/en active Active
- 2020-06-29 WO PCT/EP2020/068183 patent/WO2021001288A1/en active Application Filing
- 2020-06-29 SG SG11202112537YA patent/SG11202112537YA/en unknown
- 2020-06-29 MX MX2021015873A patent/MX2021015873A/en unknown
- 2020-06-29 KR KR1020227002600A patent/KR20220029686A/en active Search and Examination
- 2020-06-29 MA MA056440A patent/MA56440A/en unknown
- 2020-06-29 EP EP20734406.0A patent/EP3993794A1/en active Pending
- 2020-06-29 PE PE2021002218A patent/PE20221020A1/en unknown
- 2020-06-29 CN CN202311788931.8A patent/CN117700395A/en active Pending
- 2020-06-29 US US17/621,851 patent/US20220259179A1/en active Pending
- 2020-06-29 AU AU2020299953A patent/AU2020299953A1/en active Pending
- 2020-06-29 JP JP2021577411A patent/JP2022539152A/en active Pending
- 2020-06-30 AR ARP200101853A patent/AR119318A1/en unknown
- 2020-06-30 TW TW109122035A patent/TW202115010A/en unknown
-
2021
- 2021-11-08 CL CL2021002946A patent/CL2021002946A1/en unknown
- 2021-11-17 ZA ZA2021/09193A patent/ZA202109193B/en unknown
- 2021-12-23 IL IL289314A patent/IL289314A/en unknown
- 2021-12-29 CO CONC2021/0018155A patent/CO2021018155A2/en unknown
- 2021-12-29 EC ECSENADI202193559A patent/ECSP21093559A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL289314A (en) | 2022-02-01 |
| BR112021022378A2 (en) | 2022-03-08 |
| MX2021015873A (en) | 2022-02-03 |
| CN113993857B (en) | 2024-01-02 |
| US20220259179A1 (en) | 2022-08-18 |
| AR119318A1 (en) | 2021-12-09 |
| JP2022539152A (en) | 2022-09-07 |
| WO2021001288A1 (en) | 2021-01-07 |
| CO2021018155A2 (en) | 2022-01-17 |
| CN117700395A (en) | 2024-03-15 |
| CL2021002946A1 (en) | 2022-07-15 |
| EP3993794A1 (en) | 2022-05-11 |
| KR20220029686A (en) | 2022-03-08 |
| TW202115010A (en) | 2021-04-16 |
| MA56440A (en) | 2022-05-11 |
| ZA202109193B (en) | 2023-11-29 |
| ECSP21093559A (en) | 2022-02-25 |
| CA3139571A1 (en) | 2021-01-07 |
| PE20221020A1 (en) | 2022-06-16 |
| WO2021001288A9 (en) | 2021-09-02 |
| CN113993857A (en) | 2022-01-28 |
| AU2020299953A1 (en) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201911804D0 (en) | Crypotgraphy using a crypotgraphy state | |
| IL289314A (en) | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator | |
| GB2590523B (en) | A connector | |
| IL290041A (en) | A scope | |
| GB201813470D0 (en) | A drumstick | |
| ZA202103581B (en) | Novel aminophosphinic derivatives as aminopeptidase a inhibitors | |
| IL289317A (en) | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator | |
| IL277811A (en) | A substituted oxopyridine derivative | |
| GB202015090D0 (en) | Corner-protection structure for a case | |
| GB201908704D0 (en) | A plug | |
| GB2587811B (en) | A Cabinet | |
| GB201918992D0 (en) | GPR52 modulator compounds | |
| GB201918974D0 (en) | Gpr52 modulator compounds | |
| GB201916298D0 (en) | GPR52 modulator compounds | |
| IL286127A (en) | A scope | |
| GB201903335D0 (en) | A sunlounger | |
| ZAA201801446S (en) | A capsule | |
| ZAF201801447S (en) | A capsule | |
| GB2572955B (en) | A clock | |
| GB2584451B (en) | A ballast distributor | |
| PT3883865T (en) | Seal for a single serve capsule | |
| AU2019901737A0 (en) | A plug | |
| GB201918274D0 (en) | A composition | |
| GB201919216D0 (en) | Tetrahydrobenzo-quinoline sulfonamides derivative compounds | |
| AU2019900735A0 (en) | A plug |